In general, BPDCN can only be diagnosed when the tumor cells demonstrate a blastic morphology, a CD4+/CD56+ immunophenotype, and no myeloid and T or B cell-specific surface marker expression. Here, NCAM1 is linked to CD4+/CD56+ hematodermic neoplasm.